Total
0
Shares
Pharmaxis (ASX:PSX) - Chief Executive, Gary Phillips - The Market Herald
Chief Executive, Gary Phillips
Source: Sydney Morning Herald
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Pharmaceutical research company Pharmaxis (PXS) has entered a trading halt as it plans an upcoming capital raise
  • It is currently unknown how much the company is aiming to raise or where the funds will be spent
  • Company shares will be paused until Thursday, April 15, or when more details about the raise are released to the market
  • Earlier this year, the company exported the first shipment of its locally developed and manufactured drug, Bronchitol, to Georgia in the U.S.
  • Pharmaxis last traded at 7.9 cents per share on April 12

Pharmaxis (PXS) has entered a trading halt ahead of an upcoming capital raise.

So far, there are no details on how much the company is aiming to raise or where the funds will be spent.

Under the halt, company shares will be paused until Thursday, April 15, or when more details about the placement are released to the market.

Pharmaxis is an Australian pharmaceutical research company that is focussed on developing drugs for inflammatory and fibrotic diseases.

Earlier this year, the company exported the first shipment of its locally developed and manufactured drug, Bronchitol, to Georgia in the U.S.

The Bronchitol treatment has been approved in the U.S. and Australia for adults and children suffering with cystic fibrosis.

Just last month, Pharmaxis partner Chiesi launched Bronchitol in the United States.

"We expect Bronchitol sales in the U.S. to contribute strongly to the product’s global sales and profit growth, making the Pharmaxis mannitol respiratory business cash flow positive from FY 2021," CEO Gary Philips said in March.

Cystic fibrosis is a debilitating genetic disease that causes progressive damage to the lungs and other organs.

On the market, Pharmaxis last traded at 7.9 cents per share on April 12.

PXS by the numbers
More From The Market Herald
Site Group (ASX:SIT) enters $15M funding arrangement with Lucerne Investment

" Tymlez Group (ASX:TYM) gets ready to raise capital

Tymlez Group (TYM) is gearing up to raise more capital, after placing its securities in a trading halt ahead of a fundraise announcement.
DevEx Resources (ASX:DEV) to raise $8.4 million for WA and NSW projects

" Boadicea Resources (ASX:BOA) looks to raise fresh capital

Boadicea Resources (BOA) has entered a trading halt ahead of an approaching capital raise.
The Market Herald Video

" Great Boulder Resources (ASX:GBR) begins week in trading halt

Great Boulder Resources (GBR) has begun the week in a trading halt in regards to an upcoming capital raising.